TX HB975

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (drugs, biological products, or devices) that are uniquely produced based on the patient's genetic profile, including gene therapy antisense oligonucleotides and neoantigen vaccines

Requires patients to have considered all FDA-approved treatment options, provide written informed consent, and obtain physician attestation that the patient qualifies and that the treatment is recommended based on genetic analysis

Health care facilities must operate under federal human subjects protection assurances (42 U.S.C. Section 289(a) and 45 C.F.R. Part 46) to be eligible to provide these treatments

Prohibits state licensing boards from taking action against health care providers' licenses solely for recommending individualized investigational treatments, and bars state officers from blocking eligible patients' access to compliant treatments

Does not require insurers, government agencies, or hospitals to cover or provide these treatments; patients are liable for all expenses, though heirs are not responsible for treatment-related debt if the patient dies during treatment